These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 9428832)

  • 1. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.
    Garber AJ; Duncan TG; Goodman AM; Mills DJ; Rohlf JL
    Am J Med; 1997 Dec; 103(6):491-7. PubMed ID: 9428832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies.
    Fujioka K; Brazg RL; Raz I; Bruce S; Joyal S; Swanink R; Pans M
    Diabetes Obes Metab; 2005 Jan; 7(1):28-39. PubMed ID: 15642073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
    Pan C; Xing X; Han P; Zheng S; Ma J; Liu J; Lv X; Lu J; Bader G;
    Diabetes Obes Metab; 2012 Aug; 14(8):737-44. PubMed ID: 22369287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.
    Seino Y; Miyata Y; Hiroi S; Hirayama M; Kaku K
    Diabetes Obes Metab; 2012 Oct; 14(10):927-36. PubMed ID: 22583697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
    Guo L; Tian F; Liu L; Chen M; Jiang C; Li S; Liu C; Zhang Y; Qin J; Yu D; Zong Y; Dai W
    Diabetes Obes Metab; 2024 Jul; 26(7):2830-2838. PubMed ID: 38602409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
    Rosenstock J; Seman LJ; Jelaska A; Hantel S; Pinnetti S; Hach T; Woerle HJ
    Diabetes Obes Metab; 2013 Dec; 15(12):1154-60. PubMed ID: 23906374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
    Lavalle-González FJ; Januszewicz A; Davidson J; Tong C; Qiu R; Canovatchel W; Meininger G
    Diabetologia; 2013 Dec; 56(12):2582-92. PubMed ID: 24026211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
    Kovacs CS; Seshiah V; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
    Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
    Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
    Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.
    Bailey CJ; Morales Villegas EC; Woo V; Tang W; Ptaszynska A; List JF
    Diabet Med; 2015 Apr; 32(4):531-41. PubMed ID: 25381876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes.
    Aggarwal N; Singla A; Mathieu C; Montanya E; Pfeiffer AFH; Johnsson E; Zhao J; Iqbal N; Bailey C
    Diabetes Obes Metab; 2018 Feb; 20(2):463-467. PubMed ID: 28857388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong.
    Pan C; Han P; Ji Q; Li C; Lu J; Yang J; Li W; Zeng J; Hsieh AT; Chan J
    J Diabetes; 2017 Apr; 9(4):386-395. PubMed ID: 27171508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
    Fonseca V; Rosenstock J; Patwardhan R; Salzman A
    JAMA; 2000 Apr; 283(13):1695-702. PubMed ID: 10755495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
    Owens DR; Swallow R; Dugi KA; Woerle HJ
    Diabet Med; 2011 Nov; 28(11):1352-61. PubMed ID: 21781152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).
    Yu Pan C; Han P; Liu X; Yan S; Feng P; Zhou Z; Lv X; Tian H; Jin Kui Y; Su B; Shang S; Niemoeller E
    Diabetes Metab Res Rev; 2014 Nov; 30(8):726-35. PubMed ID: 24639432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study.
    Garber AJ; Bruce S; Fiedorek FT
    Clin Ther; 2002 Sep; 24(9):1401-13. PubMed ID: 12380632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
    Jabbour SA; Hardy E; Sugg J; Parikh S;
    Diabetes Care; 2014; 37(3):740-50. PubMed ID: 24144654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL; Stewart J; Issa M; Lake B; Melis R
    Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
    Ridderstråle M; Andersen KR; Zeller C; Kim G; Woerle HJ; Broedl UC;
    Lancet Diabetes Endocrinol; 2014 Sep; 2(9):691-700. PubMed ID: 24948511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
    Kadowaki T; Kondo K
    Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.